KR-20260067325-A - Method for producing magnesium-substituted Prussian blue nanoparticles, magnesium-Prussian blue nanoparticles produced therefrom, and uses thereof

Abstract

The present invention relates to a method for manufacturing magnesium-substituted Prussian blue nanoparticles and the use thereof.

Inventors

• 한형섭
• 김유찬
• 권희영
• 전호정
• 김혁

Assignees

• 한국과학기술연구원

Dates

Publication Date

20260512

Application Date

20251028

Priority Date

20241105

Claims (16)

1. 1) a step of generating a Prussian blue (PB) precipitate through a precipitation reaction by dropping a potassium ferricyanide ( K₃ [Fe(CN) ₆ ]) solution into a solution in which iron ions and a stabilizer are dissolved; and 2) A method for preparing magnesium-substituted Prussian blue (Mg-PB) nanoparticles comprising the step of mixing a solution containing magnesium ions with the above Prussian blue precipitate.
2. In paragraph 1, A method for preparing magnesium-Prussian blue (Mg-PB) nanoparticles, wherein in step 2) above, the solution containing magnesium ions is selected from the group comprising magnesium hydroxide, magnesium chloride, magnesium oxide, magnesium nitrate, and magnesium sulfate.
3. In paragraph 1, A method for preparing magnesium-Prussian blue (Mg-PB) nanoparticles, wherein the stabilizer of step 1) above is selected from the group comprising polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), citric acid, polyvinyl alcohol (PVA), polydopamine (PDA), sodium dodecyl sulfate (SDS), Tween surfactant, polymethyl methacrylate (PMMA), dextran, glutathione, cysteine, and lysine.
4. In paragraph 1, A method for manufacturing magnesium-Prussian blue (Mg-PB) nanoparticles, wherein the magnesium-Prussian blue (Mg-PB) nanoparticles have a size of 10 to 100 nm.
5. Magnesium-Prussian blue (Mg-PB) nanoparticles produced by the manufacturing method of claim 1.
6. An antioxidant comprising magnesium-Prussian blue (Mg-PB) nanoparticles prepared by the manufacturing method of claim 1.
7. A pharmaceutical composition for the prevention or treatment of diseases caused by excessive production of reactive oxygen species, comprising magnesium-Prussian blue (Mg-PB) nanoparticles produced by the manufacturing method of claim 1 as an active ingredient.
8. In Paragraph 7, A pharmaceutical composition wherein the disease caused by the excessive generation of the above-mentioned reactive oxygen species is arteriosclerosis, hypertension, ischemic disease, stroke, Parkinson's disease, Alzheimer's disease, inflammatory bowel disease, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, atopic dermatitis, cancer, diabetes, chronic ulcer, burn, or wound.
9. In paragraph 8, A pharmaceutical composition wherein the above-mentioned ischemic disease includes angina pectoris, myocardial infarction, ischemic stroke, transient ischemic attack, peripheral artery disease, renal ischemic injury, hepatic ischemic injury, or mesenteric ischemia.
10. A quasi-drug composition for the prevention or treatment of diseases caused by excessive production of reactive oxygen species, comprising magnesium-Prussian blue (Mg-PB) nanoparticles produced by the manufacturing method of claim 1 as an active ingredient.
11. A cosmetic composition for preventing or improving symptoms or diseases caused by reactive oxygen species, comprising magnesium-Prussian blue (Mg-PB) nanoparticles produced by the manufacturing method of claim 1 as an active ingredient.
12. In Paragraph 11, A cosmetic composition wherein the symptoms or diseases caused by the above-mentioned active oxygen are skin aging, wrinkle formation, skin pigmentation, atopy, acne, psoriasis, or eczema.
13. In Paragraph 11, The above cosmetic composition is an ampoule, cream, lotion, toner, essence, or pack.
14. A topical skin composition for promoting wound healing or skin regeneration, comprising magnesium-Prussian blue (Mg-PB) nanoparticles produced by the manufacturing method of claim 1 as an active ingredient.
15. A medical device comprising magnesium-Prussian blue (Mg-PB) nanoparticles produced by the manufacturing method of claim 1 as an active ingredient.
16. In paragraph 15, The above medical device is a medical device that is a wound dressing.

Description

Method for producing magnesium-substituted Prussian blue nanoparticles, magnesium-Prussian blue nanoparticles produced therefrom, and uses thereof The present invention relates to a method for producing magnesium-substituted Prussian blue nanoparticles, magnesium-Prussian blue nanoparticles produced therefrom, and uses thereof, specifically to nanoparticles produced by magnesium substitution of Prussian blue precipitates and a method for producing such nanoparticles, and uses as pharmaceutical and/or cosmetic compositions utilizing the antioxidant effect of said nanoparticles. Reactive Oxygen Species (ROS) refer to chemically reactive molecules containing oxygen atoms. ROS are a collective term for various types of oxygen that are primarily generated in mitochondria—small organelles within cells—and are more unstable and reactive than ordinary oxygen used in the body. While ROS are involved in signal transduction related to cell proliferation and differentiation, it is known that higher levels of ROS can promote cancer development and metastasis, DNA damage, or apoptosis. These ROS are known to play a significant role in the onset and progression of various intractable diseases, such as cancer, cardiovascular disease, neurological disorders, diabetes, and arthritis. These diseases are becoming serious social issues due to their high prevalence and mortality rates worldwide. In particular, the severity of these issues is intensifying, with cancer and cardiovascular disease ranking as the leading and second major causes of death. Therefore, capturing these reactive oxygen species is emerging as a promising therapeutic strategy for various diseases, and consequently, there is a growing need for the development of fundamental treatments through the elimination of reactive oxygen species. However, existing treatments, such as currently used antioxidant adjuvants, are insufficient for the direct elimination of reactive oxygen species, making fundamental treatment difficult. Therefore, there is an urgent need for the development of therapeutic agents capable of directly and effectively eliminating reactive oxygen species. However, since the development of new drugs requires ensuring long-term toxicity and stability, it is necessary to identify therapeutic agents utilizing substances with established in vivo stability. Figure 1 is a schematic diagram showing the synthesis process of MgPB nanoparticles according to the present invention. Figure 2 shows the results of visual observation of the MgPB nanoparticles synthesized in the present invention. In the case of MgPB, due to magnesium substitution, it exhibits a pale yellow color compared to the blue PB, and as a result of absorbance (UV-vis) measurement, the 700 nm peak, which is the characteristic peak of PB, did not appear in MgPB. Figure 3 shows the results of confirming the magnesium ion amount of MgPB synthesized in the present invention using an assay kit, confirming that the amount of Mg²⁺ increases in a concentration-dependent manner. Figure 4 shows the results of measuring the particle size and surface potential (zeta potential) of the synthesized MgPB nanoparticles, confirming that the size of MgPB increased by approximately 10 times and the surface potential decreased. Figure 5 is the result of TEM FFT analysis of MgPB particles, through which it was confirmed that MgPB particles also have peaks (200), (220), (400), and (420) corresponding to the crystal planes of PB, which shows that it contains particles having the same structure as PB. In addition, as a result of confirming the constituent elements through EDS mapping, C, N, Fe, K and Mg corresponding to the existing PB were detected together, indicating that magnesium is present in the PB structure. Figure 6 shows the results of measuring structural changes within the particles following the formation of magnesium-Prussian blue (MgPB) nanoparticles. Figure 7 shows the results of cyclic voltammetry analysis to confirm the redox characteristics of magnesium-Prussian blue (MgPB) nanoparticles, and it was confirmed that in the case of MgPB nanoparticles, the current amount of the redox peak increased in a concentration-dependent manner. Figure 8 shows the capture rate of peroxide measured using a hydrogen peroxide assay kit, and it was confirmed that the capture rate of MgPB nanoparticles improved in a concentration-dependent manner. Figure 9 shows the results of measuring the change in OH radicals, confirming that MgPB nanoparticles showed a reduction rate of more than 98%. Figure 10 shows the results of DPPH and ABTS analysis to confirm the antioxidant properties of MgPB, and it can be seen that the antioxidant efficiency of MgPB nanoparticles is improved compared to PB. Figure 11 shows the results of comparing the cytotoxicity of MgPB and PB. PB exhibited high reactivity and toxicity at high concentrations due to its small size, but it was confirmed that MgPB nanoparticles reduced toxicity due to inc